Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor AS703026 Given Orally to Subjects With Solid Tumours

Next Previous
Trial Profile

A Multicenter, Open Label, Phase I Trial of the MEK Inhibitor AS703026 Given Orally to Subjects With Solid Tumours

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimasertib (Primary)
  • Indications Advanced breast cancer; Colorectal cancer; Lung cancer; Malignant melanoma; Mesothelioma; Prostate cancer; Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Merck KGaA

    • Most Recent Events

    • 19 Nov 2020 Results (n=89) assessing efficacy, safety, and pharmacodynamics of pimasertib at pharmacologically active doses in patients with melanoma, published in the Targeted Oncology
    • 10 Nov 2020 After determination of MTD and/or MAD for Regimen1/Regimen2, and critical evaluation of need for a washout period between doses based on safety, PK and PD outcomes, clinical trial protocol was amended to allow for testing of continuous qd and continuous bid dosing in patients with Melanoma (since preliminary evidence of antitumor activity had been observed in melanoma patients).
    • 10 Nov 2020 Results published in the Targeted Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top